The COVID-19 vaccine developed by Sinovac Biotech has passed a WHO emergency use listing assessment – a procedure for listing unlicensed vaccines with the aim of expediting product availability amid a public health emergency. The Chinese pharmaceutical company says it has provided over 600 million vaccines worldwide, and has administered more than 430 million jabs. CGTN reporter Feng Yilei talks to Yin Weidong, chairman, president and CEO of Sinovac, about the significance of the approval.
Source：CGTN［2021-06-01］
